Literature DB >> 19960299

[Tumors of the urinary system. Current and old problems].

S Minner1, G Sauter.   

Abstract

Principally there are two different types of bladder cancer. Non-invasive papillary low grade tumors (pTa G1-G2) are genetically stable, recur frequently but show a low risk of progression. On the other hand there are high grade tumors (pT1-4, carcinoma in situ), which are genetically unstable, show biologically aggressive behaviour and progress. The distinction between non-invasive (pTa) and minimal-invasive (pT1) is one of the most challenging areas in bladder pathology. Due to the lack of appropriate auxiliary analysis the diagnosis is based entirely on histopathology. P53 immunohistochemistry can be helpful in the assessment of recurring high grade neoplasia. Targeted therapy in bladder cancer is particularly interesting, since a high number of oncogenes are activated and overexpressed (e.g. HER2 and EGFR).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19960299     DOI: 10.1007/s00292-009-1192-6

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  23 in total

1.  Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder.

Authors:  M Ugur Mungan; A Erdem Canda; Emre Tuzel; Kutsal Yorukoglu; Ziya Kirkali
Journal:  Eur Urol       Date:  2005-07-01       Impact factor: 20.096

2.  Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells.

Authors:  R Simon; E Eltze; K L Schäfer; H Bürger; A Semjonow; L Hertle; B Dockhorn-Dworniczak; H J Terpe; W Böcker
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

3.  HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications.

Authors:  Stefan Krüger; Georg Weitsch; Hartwig Büttner; Arne Matthiensen; Torsten Böhmer; Tim Marquardt; Friedhelm Sayk; Alfred C Feller; Andreas Böhle
Journal:  Int J Cancer       Date:  2002-12-10       Impact factor: 7.396

4.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.

Authors:  C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

5.  Molecular correlates of gefitinib responsiveness in human bladder cancer cells.

Authors:  Marissa Shrader; Maria Simona Pino; Gordon Brown; Peter Black; Liana Adam; Menahse Bar-Eli; Colin P N Dinney; David J McConkey
Journal:  Mol Cancer Ther       Date:  2007-01       Impact factor: 6.261

6.  C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?

Authors:  M Underwood; J Bartlett; J Reeves; D S Gardiner; R Scott; T Cooke
Journal:  Cancer Res       Date:  1995-06-01       Impact factor: 12.701

7.  Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer.

Authors:  Y C Tsai; P W Nichols; A L Hiti; Z Williams; D G Skinner; P A Jones
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

8.  Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.

Authors:  Riccardo Bartoletti; Tommaso Cai; Gabriella Nesi; Lucia Roberta Girardi; Gianna Baroni; Maurizio Dal Canto
Journal:  J Surg Res       Date:  2007-07-05       Impact factor: 2.192

9.  Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers.

Authors:  X Xu; M J Stower; I N Reid; R C Garner; P A Burns
Journal:  Clin Cancer Res       Date:  1996-10       Impact factor: 12.531

10.  The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urological Group.

Authors:  J A Witjes; L A Kiemeney; H E Schaafsma; F M Debruyn
Journal:  Br J Urol       Date:  1994-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.